GLP-1 Side Effects Beyond Weight Loss: What 2026 Data Shows
GLP-1 drugs like semaglutide and tirzepatide do more than help people lose weight. New 2026 research points to effects on the heart, brain, wound healing, and biological ageing, and tracking more than weight is how you catch them.
The heart data most users have not seen yet
A 2026 animal study found semaglutide changed the shape and behaviour of the upper chambers of the heart in rats recovering from a heart attack (PMID 42015513). In plain English, the drug did something to the heart's electrical and structural pattern that was different from a standard anti-inflammatory.
This is early work in rats, not in humans. The practical read: if you are on a GLP-1 and your heart rate or HRV on your watch has shifted since starting, that is worth raising with your prescriber at your next visit.
Epigenetic ageing: the clock finding that changes how to read a plateau
A 2026 pilot in npj Aging tracked a biological-ageing score called DunedinPACE in people on semaglutide. Participants whose ageing pace slowed were also the ones who kept losing liver fat past two months (PMID 42014432).
That reframes a plateau, if fat loss flattens but inflammation and ageing markers keep improving, the protocol is still doing the work that matters. We covered how to read this in the semaglutide plateau post.
Brain, wound healing, and teens: three signals worth knowing
A 2024 review in Molecular and Cellular Neurosciences reported GLP-1 receptors are active in brain areas tied to Alzheimer's pathology, where the drugs reduced tau and amyloid markers in animal models (PMID 42014236). Not a treatment yet, a direction research is moving.
A 2026 cohort study found a signal that people on a GLP-1 before surgery had a higher rate of wound complications after breast reconstruction (PMID 42013898). If you have elective surgery coming up, this is the single most actionable finding here: tell the surgical team well in advance.
In teens with obesity, GLP-1 therapy shifted body composition and metabolic risk markers in 2026 data (PMID 42011014). The teen story is still being written, and a cost-effectiveness analysis from the same year flagged the affordability question that follows (PMID 42013575).
What to actually track if you are on a GLP-1
Weight and waist are the obvious ones. The non-obvious ones are the markers above: resting heart rate, HRV from your watch, hs-CRP every three months, and ALT if you started in the obese range.
Mood, sleep quality, and a one-line daily note on GI symptoms. These are the three readers tell us they wish they had logged in month one. Pepture's daily check-in takes ten seconds and the biomarker rows align to your dose day.
Before elective surgery
Your prescriber and surgeon both need to know you are on a GLP-1, and they typically need to know at least two weeks out. Keep a clean one-page export from Pepture ready for that conversation.
The compounding access question
Legislative action on compounded GLP-1s is the reason many users are asking whether to stash a supply or switch to an FDA-approved brand. That is a question for your prescriber, not a blog post. What Pepture can do is keep your log intact across any brand change so the next clinician sees the full picture.
If you are weighing tirzepatide vs semaglutide based on what the SURMOUNT-5 curve looked like past month four, the Tirzepatide reference page and the Semaglutide reference page summarise what the community and the literature currently report.